Compare Stocks: YDES, ALLO, SVA, and MDXG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$2.10 +4.5%	$1.95	$0.99 ▼ $4.46	$693.76M	0.48	6.18 million shs	5.36 million shs
MDXG MiMedx Group	$4.27 -1.6%	$4.00	$3.03 ▼ $7.97	$632.60M	1.45	1.55 million shs	1.16 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.79	N/A	N/A
YDES YD Bio	$2.51 +9.1%	$2.47	$1.70 ▼ $25.00	$162.46M	N/A	38,391 shs	35,050 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+6.91%	+0.50%	-11.84%	+93.27%
MDXG MiMedx Group	0.00%	+5.08%	+5.60%	+21.91%	-38.18%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
YDES YD Bio	0.00%	+5.99%	+3.14%	-57.58%	+229,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$2.10 +4.5%	$1.95	$0.99 ▼ $4.46	$693.76M	0.48	6.18 million shs	5.36 million shs
MDXG MiMedx Group	$4.27 -1.6%	$4.00	$3.03 ▼ $7.97	$632.60M	1.45	1.55 million shs	1.16 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.79	N/A	N/A
YDES YD Bio	$2.51 +9.1%	$2.47	$1.70 ▼ $25.00	$162.46M	N/A	38,391 shs	35,050 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+6.91%	+0.50%	-11.84%	+93.27%
MDXG MiMedx Group	0.00%	+5.08%	+5.60%	+21.91%	-38.18%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
YDES YD Bio	0.00%	+5.99%	+3.14%	-57.58%	+229,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.52	305.82% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.50	99.06% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest YDES, ALLO, SVA, and MDXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/18/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	36,240.75	N/A	N/A	$1.30 per share	1.62
MDXG MiMedx Group	$418.63M	1.49	$0.55 per share	7.83	$1.73 per share	2.47
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.77	N/A	N/A	N/A	N/A	-56.45%	-40.36%	8/12/2026 (Estimated)
MDXG MiMedx Group	$48.58M	$0.04	106.78	25.12	N/A	1.76%	12.09%	9.22%	N/A
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/13/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest YDES, ALLO, SVA, and MDXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	N/A	N/A	N/A	$0.00 million	N/A
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million
5/13/2026	Q1 2026	ALLO Allogene Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.65	9.65
MDXG MiMedx Group	0.07	5.33	4.79
SVA Sinovac Biotech	0.04	4.59	4.53
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
MDXG MiMedx Group	79.15%
SVA Sinovac Biotech	N/A
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
MDXG MiMedx Group	2.50%
SVA Sinovac Biotech	12.79%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	345.15 million	299.60 million	Optionable
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable
YDES YD Bio	N/A	70.79 million	N/A	N/A

YDES, ALLO, SVA, and MDXG Headlines

Recent News About These Companies

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

YD Bio Ltd.

June 25, 2026 | barrons.com

Yd Bio

June 25, 2026 | fool.com

YD Bio Analyst Ratings and Price Targets | NASDAQ:YDES | Benzinga

June 25, 2026 | benzinga.com

YD Bio Limited Reports Financial Results for Full Year 2025, Achieves 17% Revenue Growth and Strategic Advances in Healthcare Innovations

April 30, 2026 | quiverquant.comQ

YD Bio Limited Reports Full Year 2025 Financial Results

April 30, 2026 | globenewswire.com

YD Bio Ltd YDES

April 4, 2026 | morningstar.comM

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

March 31, 2026 | globenewswire.com

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

March 17, 2026 | globenewswire.com

YD Bio Forms Taiwan-U.S. Dual-Core FDA Regulatory Platform in Alliance with YC Biotech

February 26, 2026 | tipranks.com

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

February 25, 2026 | globenewswire.com

YDES YD Bio Limited

February 25, 2026 | seekingalpha.com

YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC

January 30, 2026 | tipranks.com

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

January 29, 2026 | globenewswire.com

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

January 6, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

YDES, ALLO, SVA, and MDXG Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$2.10 +0.09 (+4.48%)

As of 04:00 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

MiMedx Group NASDAQ:MDXG

$4.27 -0.07 (-1.61%)

As of 04:00 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 08/7/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

YD Bio NASDAQ:YDES

$2.51 +0.21 (+9.13%)

As of 03:59 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YDES, ALLO, SVA, and MDXG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YDES, ALLO, SVA, and MDXG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YDES, ALLO, SVA, and MDXG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

YDES, ALLO, SVA, and MDXG Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

MiMedx Group NASDAQ:MDXG

Sinovac Biotech NASDAQ:SVA

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YDES, ALLO, SVA, and MDXG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YDES, ALLO, SVA, and MDXG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YDES, ALLO, SVA, and MDXG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

YDES, ALLO, SVA, and MDXG Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

MiMedx Group NASDAQ:MDXG

Sinovac Biotech NASDAQ:SVA

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools